CMND Clearmind Medicine Inc. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1892500 · Fiscal year ends 10/31
Financial factors as of 2026-01-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-33.9%
TTM EPS YoY68.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-119.7%
ROA-74.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets26.1%
Debt / equity0.00x
Current ratio3.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-12.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-10-31 | FY2024*2024-10-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.06M | $1.38M |
| SG&A expense | $3.61M | $4.36M |
| Interest expense | $3,857 | $5,386 |
| Pretax income | -$3.79M | -$4.88M |
| Income tax | $70,445 | $377,966 |
| Net income | -$3.86M | -$5.25M |
| EPS (basic) | -30.35 | -67.80 |
| EPS (diluted) | -30.35 | -67.80 |
| Weighted avg. shares (diluted) | 127,093 | 77,503 |
| Balance sheet | ||
| Cash & equivalents | $3.92M | $6.57M |
| Short-term investments | $1.66M | $289,388 |
| Current assets | $5.95M | $7.09M |
| Intangibles | $97,372 | $108,326 |
| Total assets | $6.08M | $7.26M |
| Current liabilities | $4.89M | $4.13M |
| Total liabilities | $4.89M | $4.15M |
| Shareholders' equity | $1.19M | $3.11M |
| Cash flow statement | ||
| Operating cash flow | -$4.73M | -$4.86M |
| Investing cash flow | -$542,017 | -$238,097 |
| Financing cash flow | $2.62M | $6.25M |
| Stock-based compensation | $805,890 | $998,918 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.